Initiator Pharma A/S (STO:INIT)

Market Cap	224.53M -33.6%
Revenue (ttm)	n/a
Net Income	-19.83M
EPS	-0.32
Shares Out	68.45M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	78,742
Average Volume	182,848
Open	3.300
Previous Close	3.350
Day's Range	3.240 - 3.370
52-Week Range	2.560 - 6.600
Beta	0.07
RSI	54.49
Earnings Date	May 8, 2026

About Initiator Pharma

Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor, which completed phase IIb clinical trial primarily targeting the dopamine system for treatment resistant organic erectile dysfunction, as well as completed phase I to treat neuropathic pain; and IP2018, a monoamine reuptake inhibitor which completed Phase IIa for the treatment of psychogenic erectile dysfunction. The ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 1
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: INIT

Financial Performance

Financial numbers in DKK